Shoppers Drug Mart partners with Avicanna to transition Medical Cannabis by Shoppers

Avicanna Inc (TSX:AVCN, OTCQX:AVCNF), a biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products, revealed that Shoppers Drug Mart has selected the company as its partner to transition its Medical Cannabis by Shoppers business.

The Toronto-based company said Shoppers will continue to support patients throughout the transfer of assets and services to Avicanna, which it anticipates will take place over the next three months.

First launched in Ontario in January 2019, Medical Cannabis by Shoppers provides patients access to medical cannabis products from over 30 licensed cannabis brands. Over the past four years, the platform has supported tens of thousands of patients and has worked with patient groups to make access to medical cannabis easier.

“We are grateful for the trust placed in us by our medical cannabis patients over the past few years, and are confident we’ve found the right partner in Avicanna to continue to support them,” said Shoppers Drug Mart president Jeff Leger in a statement.  

“As we move away from medical cannabis distribution, we remain firm in our belief that this medication should be dispensed in pharmacies like all others and will continue our advocacy to that end.”

MyMedi.ca to aid medical cannabis patients 

As part of the transition, Avicanna will introduce MyMedi.ca, a new medical cannabis care platform designed to enhance the patient journey. MyMedi.ca will have pharmacist-led patient support programs and aims to provide a similar product portfolio including various formats, brands, and competitive pricing.

“We are thankful to be selected as the partner for this transition and look forward to introducing MyMedi.ca, with a view towards supporting patients and facilitating continuity of care,” said Avicanna CEO Aras Azadian.

“We are motivated towards furthering the work started by Shoppers to create Canada’s leading independent, comprehensive medical cannabis platform and continuing our efforts towards advancing access to medical cannabis and its long-term incorporation into the standard of care.”

Avicanna noted that with initial transitional support from the Medical Cannabis by Shoppers team, MyMedi.ca will provide a “scientifically curated and diverse formulary of products,” and comprehensive training programs for the medical community.

The online medical portal will also focus on patient education in areas such as harm reduction and will continue to provide specialty services to distinct patient groups including veterans, in addition to reimbursement services for public and private providers, added the company.

Avicanna has a scientific platform and clinical development that has led to the commercialization of over 30 products. The firm’s medical cannabis and wellness products are marketed under the RHO Phyto brand and contain cannabinoids. In addition, Avicanna has developed a pipeline of drug candidates that are in clinical development and commercialization. The cannabinoid-based drug candidates look to address medical needs in the areas of dermatology, chronic pain, and neurological disorders.

Contact the author Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive

Read more here: Source link

Leave a Reply

Your email address will not be published. Required fields are marked *